Transcript symptom management of palliative patients in the ICU

Symptom Management in
Palliative ICU Patients
With a Focus on Pain, Dyspnea, and
Addressing in the Palliative Withdrawal of
Ventilatory Support in the Awake Patient
Mike Harlos MD, CCFP, FCFP
Professor and Section Head, Palliative Medicine, University of Manitoba
Medical Director, WRHA Adult and Pediatric Palliative Care
http://palliative.info
Objectives
•
Appreciate the common physical symptoms experienced
by palliative patients in the ICU
•
Review the common approaches for symptom control at
the end of life, particularly pain and dyspnea
•
Discuss therapeutic considerations prior to ventilator
withdrawal especially in the awake patient
The presenter has no conflict
of interest to disclose
There are no “do-overs”
in managing a death
Addressing Comfort During
Palliative Withdrawal Of Life-
Sustaining Ventilatory Support in
the Awake Patient
Assumptions
•
the circumstances being considered pertain to patients
expected to die without support (‘terminal wean’) rather
than a trial of weaning for potential ICU discharge
•
may include patients with stenting endotracheal tubes for
obstructing tumour, with normal resp drive and strength
•
in response to the informed request of the awake and
competent patient or their proxy/surrogate decision
maker
•
focuses on the practical/clinical considerations involved
in ensuring comfort during withdrawal of ventilator
support, particularly in the alert patient
Examples of Our Palliative Care Experiences
•
74 yo man with multisystem failure due to primary amyloidosis
- respiratory failure, on dialysis, TPN, pressor infusion
- transferred directly from SBGH ICU to a farm two hours out of
town on which he was born, and which his family homesteaded.
•
52 yo woman with untreatable obstructing mediastinal tumour, in
ICU with stenting endotracheal tube, requesting extubation
•
63 yo man with obstructing laryngeal tumour, intubated in spite of
clear wishes to the contrary after collapsing in the community with
acute obstruction
- once he awoke in SICU he demanded extubation
- wanted no meds given – wanted to say goodbye to his children
with his own voice if possible
•
71 yo man with advanced ALS, locked-in (only motor function was
right lateral gaze of the right eye), wanting vent withdrawal in the
home
General Considerations In Withdrawing Ventilatory
Support In The Awake Patient Expected To Die
•
facilitating saying good-bye to family and friends, and
perhaps the health care team
•
the concept of picking a date and time of death may
seem surreal
•
the potential for severe distress is very real – and
predictable
•
very challenging to gauge potential for patient to breathe
unsupported after withdrawal
- not uncommon for the person who “never triggers the
vent” to breathe for hours or days following withdrawal
Exploring Issues/Concerns With Patient, Family,
Team Prior To Withdrawal
•
difference between withdrawing ventilator and euthanasia
- allowing the death to unfold naturally from the
underlying illness, as it would have done
•
the issue of “playing God”
•
staff feelings of moral/professional/religious compromise
•
need for pre-briefings, de-briefings, education, mediation,
supportive counseling
•
what they can expect to see
•
the outcome is not always certain
How Alert Is The Patient?
•
if alert and no CNS impairment (such as with ALS or an
obstructing tumour stented with an ET tube) must
ensure a deep level of sedation prior to beginning
withdrawal of ventilatory support
•
if the patient has suffered a devastating neurological
injury and is deeply comatose, there is less potential for
experiencing air hunger
Anticipatory (Preemptive) vs. Reactive Medications
•
reactive dosing essentially requires suffering
•
the impact of the medication delivery system must be
considered in reactive dosing, e.g.
- PCA bolus on a pump with long tubing, vs. manual
push into port near the patient
•
pharmacokinetics of different opioids not always taken
into consideration when planning reactive dosing
•
pharmacokinetics of infusions for anticipatory dosing also
not always considered – loading dose needed
•
the concept of "anticipatory dosing" (as opposed to reactive
dosing) should guide clinicians in the use of sedation and
analgesia at the end of life
•
the rapid withdrawal of mechanical ventilation is an example of
the need for anticipatory dosing
•
reactive dosing not sufficient
•
as a general rule, the doses of medication that the patient has
been receiving hourly should be increased by two- or three-fold
and administered acutely before withdrawing mechanical
ventilation
•
Slow vs. Fast Withdrawal?
- “the only justification for gradual reduction of ventilatory support is
to allow time to control dyspnea through the titration of medications”
•
Extubate or not?
- considerable variation RE whether to extubate; each circumstance
should be approached individually
- extubation before death is associated with higher family satisfaction
(Hinkle LJ, Bosslet GT, and Torke AM. Factors associated with family
satisfaction with end-of-life care in the ICU: a systematic review. Chest.
United States; 2015;147(1):82-93)
Titration of Analgesics and Sedatives: increase in response to:
1. patient's request
2. signs of respiratory distress
3. physiological signs: unexplained tachycardia, hypertension,
diaphoresis,
4. facial grimacing, tearing, vocalizations with movements, turns or
other nursing care
5. restlessness
The total amount of drugs required for any individual patient may far
exceed any preconceived notions of “usual”
Paraphrased: If the patient tells you they’re in distress, or it looks like
they’re in distress, treat with an effective dose of medication
Does a Maximal Dose of Opioids or Sedatives Exist?
No.
The goal of palliative care is to provide relief of pain and suffering
and whatever the amount of drugs that accomplishes this goal is the
amount that is needed for that individual patient.
Paraphrased: The correct dose of an opioid or sedative is the one
that works, proportionate to distress and within acceptable adverse
effects
Should Analgesics and Sedatives be Administered in Response
to Signs and Symptoms of Pain and Suffering, or Before They
Begin?
Support for both approaches exists among lntensivists on this panel.
Paraphrased: Yes. If the patient is in pain, treat the pain. If you’re
about to do something that will likely hurt, treat preemptively.
Onset of Opioid Effect
Ref: Geriatric Anesthesiology 2nd Edition 2008; Jeffrey Silverstein (Editor),
Alec Rooke (Editor), J. G. Reves (Editor), Charles H. McLeskey (Editor);
Springer Publications
Determined by:
• route of administration
• dose
• pharmacokinetics determining plasma
concentrations over time
• rate of blood-brain equilibration between the
plasma and the site of drug effect
Ref: Geriatric Anesthesiology 2nd Edition 2008; Jeffrey Silverstein (Editor), Alec
Rooke (Editor), J. G. Reves (Editor), Charles H. McLeskey (Editor); Springer
Publications
Barr J et al; American College of Critical Care Medicine. Clinical practice
guidelines for the management of pain, agitation, and delirium in adult
patients in the intensive care unit. Crit Care Med; 2013;41(1):263-306.
How Effectively Can You Gauge Distress?
•
locked-in / advanced ALS – may lack usual visual cues
of distress – these patients also have virtually no
capability for unsupported breathing
•
vital signs (tachycardia or elevated blood pressure) may
not reliably reflect discomfort
- medication effects (e.g. scopolamine) or physiologic
changes (e.g. hypoxia) may result in changes in vital
signs without patient necessarily experiencing
discomfort
•
the inability to adequately gauge distress compels an
effective preemptive approach to ensure that air hunger
could not possibly be present
•
71 yo man “locked-in” with advanced ALS dx approx 18 mo. earlier
•
trach/vent support at home; very capable spouse as main caregiver
•
consistently expressed wish to be withdrawn from ventilator once
communication severely impaired – that time had come
•
still had right lateral movement of his right eye; through yes/no
questions could indicate that he wanted withdrawal
•
did not want to leave home – however it was not clear that a home
vent withdrawal had been done before in Winnipeg
•
resp team described absent ability to trigger vent
•
Challenges
- could not assess distress due to locked-in state, severe motor
impairment
- published protocols describing terminal vent withdrawal relied on
morphine and on reactive dosing in response evidence of distress
- local colleagues expressed significant concern with an approach
involving aggressive administration of opioids and sedatives
•
Outcome
- reviewed plan of using high-dose opioids and midazolam with
Ethics (including international discussion list), CPSM, Medical
Examiner – all were supportive
- attended patient’s home the day after Halloween (per patient’s
request – wanted to see children enjoying Halloween); lots of
family present, priest present
- administered morphine, midazolam, haloperidol, scopolamine
- withdrew ventilatory support; deceased 10 minutes later
Respiratory Physiology For The Palliative MD
• opioids
• CNS pathology
• ALS
Brain (or brainstem) says “breathe”
Nerves transmit this message on to the muscles
• Muscular
dystrophy
Muscles do the work of breathing
• Pulm. fibrosis
Lungs Exchange Air
• Severe blood
loss
Blood Transports Oxygen
• Mitochondrial
disorders
Tissues Use Oxygen
Series circuit wiringif one component fails, they all fail
• opioids
Brain (or brainstem) says “breathe”
• CNS pathology
• ALS
Nerves transmit this message on to the muscles
• Muscular
dystrophy
• Pulm. fibrosis
 “zero” capability in any
Muscles do the work of breathing element means zero
overall
Lungs Exchange Air
• Severe blood
loss
Blood Transports Oxygen
• Mitochondrial
disorders
Tissues Use Oxygen
 “zero” not that common
– e.g. locked-in ALS
 in the context of zero
resp. capability due to
severe illness, opioids
cannot make zero
worse than zero – no
fatal or compromising
dose
 must err on the side of
aggressive dosing in
vent withdrawal
•
Prepare for addressing:
- dyspnea
- anxiety
- secretions
- nausea/vomiting from opioid boluses
- seizures?
- potential for temporarily needing oral airway after
extubation – at least until best positioning found
- post-extubation stridor? (Khemani RG, Randolph A,
and Markovitz B. Corticosteroids for the prevention and
treatment of post-extubation stridor in neonates, children
and adults. Cochrane Database Syst Rev. England;
2009;(3))
•
families should be prepared for certain physical changes
that can’t be prevented – cyanosis, mottling, occasionally
some movements
My Usual Approach
1. Continue existing opioid and sedative infusions
2. Approx. 30 minutes prior to beginning the withdrawal, administer
intravenously:
- morphine (dose depends on existing opioid tolerance), or
fentanyl (if already on a fentanyl infusion)
- methotrimeprazine – e.g. 25 mg IV – antinauseant, sedative
- scopolamine 0.6 mg
- midazolam – typically 2.5 – 5 mg; depends on existing tolerance
3.
4.
5.
6.
– The patient should now be deeply asleep –
Reduce ventilatory support “by about half” for 10 minutes (Resp.
Therapists take care of the details of this for me)
Consider repeating midazolam and morphine at this time, depending
on assessment of patient’s level of sedation
Discontinue ventilator
If needed administer “unit doses” of fentanyl + midazolam –
premixed in individual syringes (e.g. 100 mcg fentanyl plus 2 mg
midazolam) – in response to distress
What Is The Correct Opioid Dose For Safely
Ensuring Comfort During Terminal Wean/Extubation?
Somewhere in here
Not
Enough
Too
Much
Put another way – there are only three doses of opioids in
such circumstances:
1. Not enough
2. Just right
3. Too much
Not enough is unconscionable; just right is unrealistic.
If we are going to err on the side of allowing a suffocating
death versus potentially hastening a relentless and certain
progression towards a natural death, which side should
we err on?
Whose needs are being met by conservative dosing?
DOCTRINE OF DOUBLE EFFECT
From Principles of Biomedical Ethics, Beauchamp & Childress; 7th Ed. 2013
Four conditions or elements that must be satisfied for an act with a double
effect to be justified. Each is a necessary condition, and together they
form sufficient conditions of morally permissible action:
1. The nature of the act. The act must be good, or at least morally
neutral (independent of its consequences)
2. The agent's intention. The agent intends only the good effect.
The bad effect can be foreseen, tolerated, and permitted, but it
must not be intended.
3. The distinction between means and effects. The bad effect must
not be a means to the good effect. If the good effect were the
direct causal result of the bad effect, the agent would intend the
bad effect in pursuit of the good effect.
4. Proportionality between the good effect and the bad effect. The
good effect must outweigh the bad effect. That is, the bad effect
is permissible only if a proportionate reason compensates for
permitting the foreseen bad effect
•
considerations about appropriate opioid doses in
terminal extubation are pretty much the only
circumstances where the Doctrine of Double Effect
feels potentially relevant in palliative care practice
•
personal experience – not one circumstance where I
felt I needed to “invoke the Doctrine”
• studies on post-ICU patients showed that 82%
remembered pain or discomfort associated with the
endotracheal tube and 77% remembered experiencing
other moderate to severe pain during their ICU stay
• pain assessment in the non-verbal patient challenging
Approach To Pain Control in the Palliative Patient
1. Thorough assessment
• History – (challenging in the non-communicative patient) - including
detailed description of pain; psychosocial, spiritual, & cultural
context; concerns about what the pain means; medication history
• Physical Examination
2. Pause here - discuss with patient/family the goals of care, hopes,
expectations, anticipated course of illness. This will influence
consideration of investigations and interventions
3. Investigations – X-Ray, CT, MRI, etc - if they will affect approach to
care
4. Treatments – pharmacological and non-pharmacological; interventional
analgesia (e.g. spinal); RadTx
5. Ongoing reassessment and review of options, goals, expectations, etc.
American College of Critical Care Medicine Clinical practice
guidelines: Recommendations RE Pain Assessment
i.
We recommend that pain be routinely monitored in all adult ICU
patients
ii.
The Behavioral Pain Scale (BPS) and the Critical-Care Pain
Observation Tool (CPOT) are the most valid and reliable behavioral
pain scales for monitoring pain in medical, postoperative, or trauma
(except for brain injury) adult ICU patients who are unable to selfreport and in whom motor function is intact and behaviors are
observable.
iii.
We do not suggest that vital signs (or observational pain scales that
include vital signs) be used alone for pain assessment in adult ICU
patients
iv.
We suggest that vital signs may be used as a cue to begin further
assessment of pain in these patients, however
A Visual Analogue Scale Developed For Nonverbal Children –
May Be Used In Nonverbal Adults
TYPES OF PAIN
NOCICEPTIVE
Somatic
•
•
•
•
•
•
•
bones, joints
connective tissues
muscles
sharp
dull & aching
can localize site
may be worse with
movement
(“incident pain”)
Visceral
NEUROPATHIC
• difficult to describe; not a
typical “pain”
• numb; burning; tingling;
crawling; stabbing; etc
• allodynia
• consider it as a possible
element of any difficult
pain syndrome
• Organs –
heart, liver,
pancreas, gut,
etc.
• may be crampy, or
dull & aching
• referred pain
• difficult to localize
• important to have at least a working assumption of the
underlying pain mechanism
- not all pain syndromes are expected to respond fully to
opioids – specifically neuropathic pain
• difficult to diagnose neuropathic pain if communication limited.
Consider if:
- previous diagnosis of neuropathic pain
- solid tumours (not just ones involving nerve plexus or spinal
cord)
- predisposing medical conditions or medications (diabetes
mellitus, chemotherapies such as cisplatin etc)
- ischemic limbs (nerves are damaged by the ischemia)
- bone mets – increasing evidence for a neuropathic element
Opioid Selection
•
for parenteral administration, typically use morphine, hydromorphone,
or fentanyl
•
selection depends on comorbidities, previous adverse reactions
•
morphine and hydromorphone have active metabolites that
accumulate in renal insufficiency and are implicated in the
development of opioid-induced neurotoxicity
•
fentanyl has no known active metabolites; preferred in renal insuff
•
parenteral methadone would be a very useful medication, however
not available in Canada (is available in UK, Europe, Australia, USA)
•
methadone: NMDA receptor antagonism; may help in neuropathic
pain, situations of high opioid tolerance, or opioid-induced
neurotoxicity
- caution RE drug interactions, QTc interval prolongation
- no known active metabolites; preferred in renal insuff
Basic Conversions – Starting Points For Consideration
Drug Conversion
Notes
morphine:hydromorphone
5 mg morphine = 1 mg
hydromorphone
hydromorphone is about 5 times more
potent than morphine
fentanyl:morphine (parenteral)
100 mcg (0.1 mg) fentanyl = 10 mg
morphine
fentanyl is about 100 times more potent
than morphine
morphine:oxycodone
1.5 mg morphine = 1 mg
oxycodone
oxycodone is about 1.5 times more
potent than morphine
methadone:anything
Context dependent
Cautions:
• particularly in high doses, tolerance to one opioid will not be fully crossed over
to another (incomplete cross-tolerance) – consider reducing converted dose
•
in the context of opioid-induced neurotoxicity, there are no conversion ratios
Parenteral Adjuvants To Consider For Neuropathic Pain
1. Ketamine (NMDA receptor antagonist)
•
•
Taylor M, Jakacki R, May C, Howrie D, and Maurer S. Ketamine PCA for Treatment
of End-of-Life Neuropathic Pain in Pediatrics. Am J Hosp Palliat Care. 2014
Kim K, Mishina M, Kokubo R, Nakajima T, Morimoto D, Isu T, Kobayashi S, and
Teramoto A. Ketamine for acute neuropathic pain in patients with spinal cord injury.
J Clin Neurosci. Scotland; 2013;20(6):804-7.
2. Dexmedetomidine (alpha-2 agonist)
•
•
•
Hilliard N, Brown S, and Mitchinson S. A case report of dexmedetomidine used to
treat intractable pain and delirium in a tertiary palliative care unit. Palliat Med.
England; 2015;29(3):278-81
Ghobadifar MA, Pourghashdar F, Akbarzadeh A, and Mosallanejad Z. Combined
use of intrathecal opioids and dexmedetomidine in the management of neuropathic
pain. Korean J Pain. Korea (South); 2015;28(2):156-7
O'Neil T, Rodgers PE, and Shultz C. Dexmedetomidine as adjuvant therapy for
acute postoperative neuropathic pain crisis. J Palliat Med. United States;
2014;17(10):1164-6
Spectrum of Opioid-Induced Neurotoxicity
1. discontinue the offending opioid
2. aggressive hydration; may need to monitor electrolytes
3. use prn doses of opioid-naïve doses of fentanyl – e.g. 50-100 mcg IV
q15 min prn (unless it is the offending opioid)
4. after several hours, determine a fentanyl infusion rate
5. consider: ketamine (NMDA antagonist) to reduce extreme opioid
tolerance
Dyspnea In The Palliative Patient
• an uncomfortable awareness of breathing… an
experience of breathlessness rather than an observation
of increased work of breathing
• increasing incidence as death nears; can escalate quickly
resulting in missed opportunities for comfort measures
• severe dyspnea in the context of advances terminal
illness usually reflects imminent death
• n = 96 patients mechanically vented > 24h
• dyspnea evaluated on a “yes–no” basis
• if yes, it was followed by a visual analog scale (VAS) and
descriptor choice (“air hunger” and/or “respiratory effort”)
• Pain & anxiety also assessed by VAS
•
47% reported dyspnea
•
dyspnea was significantly associated with anxiety (odds ratio 8.84)
•
adjusting ventilator settings improved dyspnea in 35% of patients
No dyspnea
Dyspnea - resp effort
Dyspnea - air hunger
Dyspnea - both
Dyspnea - neither
Addressing Dyspnea In The Palliative Patient
• gold standard for assessment is patient report, as with any
experiential symptom
• in the non-verbal patient, the usual clinical assessment is a
combination of:
- work of breathing – which may be absent in a ventilated
patient (increased rate, accessory muscle use)
- evidence of distress (fearful look, restless, tachycardia)
- “gut feeling” on the part of clinicians and family
• in the dying palliative patient in ICU the most likely situation
will be that of a restless patient who seems generally
uncomfortable, for uncertain reasons
• should rule out obvious reversible causes of distress, and
treat with opioids; will address pain and air hunger
American College Of Chest Physicians Consensus
Statement On The Management Of Dyspnea In Patients
With Advanced Lung Or Heart Disease - 2010
• Regarding fear of respiratory depression –
• higher doses of opioids and benzodiazepines used in the
withdrawal of life-sustaining treatment were not associated with
a decreased time from withdrawal of life support to death
• Of 11 studies providing information on ABGs or O2 sat, only one
study reported any significant changes in oxygenation after
opioid administration
• Recommend that:
• Oral and/or parenteral opioids can provide relief of dyspnea.
• Opioids should be dosed and titrated for the individual patient
with consideration of multiple factors (e.g., renal, hepatic,
pulmonary function, and current and past opioid use) for relief
of dyspnea.
•
Official American Thoracic Society Statement: Update on
the Mechanisms, Assessment, and Management of
Dyspnea – 2012
- Opioids have been the most widely studied agent in the
treatment of dyspnea. Short-term administration reduces
breathlessness in patients with a variety of conditions,
including advanced COPD, interstitial lung disease,
cancer, and chronic heart failure
• Canadian Thoracic Society Clinical Practice Guideline
2011: Managing Dyspnea In Patients With Advanced
Chronic Obstructive Pulmonary Disease
- “We recommend that oral (but not nebulized) opioids be
used for the treatment of refractory dyspnea in the
individual patient with advanced COPD”
• may reduce overall oxygen demand
• “The administration of sedatives (midazolam and morphine) has been
associated with decreases in oxygen demand and the attenuation of the
cardiopulmonary response associated with increased work of breathing”
• see also: Endoh H et al; Effects of naloxone and morphine on acute
hypoxic survival in mice. Crit Care Med; 1999;27(9):1929-33
-
significantly lower oxygen consumption and improved survival in
morphine treated rats subjected to acute hypoxic hypoxia
Common Concerns About Aggressive Use
of Opioids at End-Of-Life
• How do you know that the aggressive use
of opioids for dyspnea doesn't actually bring
about or speed up the patient's death?
• “I gave the last dose of morphine and he
died a few minutes later… did the
medication cause the death?”
1. Literature: the literature supports that opioids
administered in doses proportionate to the degree
of distress do not hasten death and may in fact
delay death
2. Clinical context: breathing patterns usually seen in
progression towards dying (clusters with apnea,
irreg. pattern) vs. opioid effects (progressive
slowing, regular breathing; pinpoint pupils)
3. Medication history: usually “the last dose” is the
same as those given throughout recent hours/days,
and was well tolerated